Total (n = 428) | Active group (n = 188) | Inactive group (n = 240) | p value | |
---|---|---|---|---|
Age, years | 31.8 ± 9.5 | 31.8 ± 9.9 | 31.8 ± 9.1 | 0.26 |
Female, n (%) | 393 (91.8) | 174 (92.6) | 219 (91.3) | 0.63 |
Disease duration, months (Q1, Q3) | 53 (29, 99) | 52 (29, 107) | 54 (31, 96) | 0.51 |
Median follow-up time, months (Q1, Q3)# | 49 (28, 85) | 33 (25, 61) | 64 (34, 98) | < 0.001 |
BVAS scores | 6.7 ± 3.7 | 7.0 ± 3.7 | 6.4 ± 3.7 | 0.10 |
VDI scores | 2.7 ± 1.8 | 2.8 ± 2.0 | 2.6 ± 1.6 | 0.28 |
Laboratory test results | ||||
ESR, mm/1st hour | 17.1 ± 19.6 | 25.6 ± 25.1 | 10.4 ± 9.4 | < 0.001 |
ESR > 20 mm/1st hour, n (%) | 106/421* (25.2) | 78/186* (41.9) | 28/235* (11.9) | < 0.001 |
hsCRP, mg/L | 13.2 ± 26.7 | 25.6 ± 36.2 | 3.4 ± 5.5 | < 0.001 |
hsCRP > 8 mg/L, n (%) | 141/410* (34.4) | 115/181* (63.5) | 26/229* (11.4) | < 0.001 |
IL-6, pg/ml | 13.9 ± 40.0 | 21.2 ± 42.3 | 7.4 ± 36.7 | 0.003 |
IL-6 > 5.9 pg/ml, n (%) | 82/241* (34.0) | 64/114* (56.1) | 18/127* (14.2) | < 0.001 |
TNFα, pg/ml | 16.3 ± 34.2 | 19.9 ± 44.3 | 13.0 ± 21.3 | 0.02 |
TNFα > 8.1 pg/ml, n (%) | 104/238* (43.7) | 54/112* (48.2) | 50/126* (39.7) | 0.19 |
Repeated vascular Doppler image results compared to former results | ||||
Stable | 175 (40.1%) | 27 (14.4%) | 148 (61.7%) | |
Improved | 15 (3.5%) | 2 (1.1%) | 13 (5.4%) | |
Progressed | 238 (55.6%) | 159 (84.6%) | 79 (32.9%) |